Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RD133 in MSLN-Positive Solid Tumors
NCT05166070Phase 1Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jan 2022
- Primary completion
- Jan 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of RD133 in solid tumor, sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Dose-Limiting Toxicity at 2 years. Started Jan 2022; status: recruiting.
02
Drugs
RD133
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05166070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05166070.